Which drugs may be hit with negotiations if the reconciliation bill passes? Wall St. analysts explain

Beyond the back and forth of whether Democrats’ drug price negotiation plan is necessary to bring down costs, or just a thinly veiled attempt at price controls, the nuts and bolts of the deal mean pharma companies will inevitably see the tail ends of certain small molecule and biologic sales...

Click to view original post